Differential Activation of Insulin Receptor Substrates 1 and 2 by Insulin-Like Growth Factor-Activated Insulin Receptors
- 1 May 2007
- journal article
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 27 (10) , 3569-3577
- https://doi.org/10.1128/mcb.01447-06
Abstract
The insulin-like growth factors (insulin-like growth factor I [IGF-I] and IGF-II) exert important effects on growth, development, and differentiation through the IGF-I receptor (IGF-IR) transmembrane tyrosine kinase. The insulin receptor (IR) is structurally related to the IGF-IR, and at high concentrations, the IGFs can also activate the IR, in spite of their generally low affinity for the latter. Two mechanisms that facilitate cross talk between the IGF ligands and the IR at physiological concentrations have been described. The first of these is the existence of an alternatively spliced IR variant that exhibits high affinity for IGF-II as well as for insulin. A second phenomenon is the ability of hybrid receptors comprised of IGF-IR and IR hemireceptors to bind IGFs, but not insulin. To date, however, direct activation of an IR holoreceptor by IGF-I at physiological levels has not been demonstrated. We have now found that IGF-I can function through both splice variants of the IR, in spite of low affinity, to specifically activate IRS-2 to levels similar to those seen with equivalent concentrations of insulin or IGF-II. The specific activation of IRS-2 by IGF-I through the IR does not result in activation of the extracellular signal-regulated kinase pathway but does induce delayed low-level activation of the phosphatidylinositol 3-kinase pathway and biological effects such as enhanced cell viability and protection from apoptosis. These findings suggest that IGF-I can function directly through the IR and that the observed effects of IGF-I on insulin sensitivity may be the result of direct facilitation of insulin action by IGF-I costimulation of the IR in insulin target tissues.Keywords
This publication has 60 references indexed in Scilit:
- Insulin-like growth factor-I treatment of growth disorders, diabetes mellitus and insulin resistanceTrends in Endocrinology & Metabolism, 2005
- Irs–2 Mediates the Antiapoptotic Effect of Insulin in Neonatal HepatocytesHepatology, 2004
- The Role of the M6P/IGF-II Receptor in Cancer: Tumor Suppression or Garbage Disposal?Hormone and Metabolic Research, 2004
- Decreasing IRS-2 expression in pancreatic β-cells (INS-1) promotes apoptosis, which can be compensated for by introduction of IRS-4 expressionMolecular and Cellular Endocrinology, 2003
- Insulin/Insulin-like Growth Factor I Hybrid Receptors Have Different Biological Characteristics Depending on the Insulin Receptor Isoform InvolvedJournal of Biological Chemistry, 2002
- Interaction of Insulin Receptor Substrate-2 (IRS-2) with the Insulin and Insulin-like Growth Factor I Receptors: EVIDENCE FOR TWO DISTINCT PHOSPHOTYROSINE-DEPENDENT INTERACTION DOMAINS WITHIN IRS-2Published by Elsevier ,1996
- Mutation of a Conserved Amino Acid Residue (Tryptophan 1173) in the Tyrosine Kinase Domain of the IGF-I Receptor Abolishes Autophosphorylation but Does Not Eliminate Biologic FunctionPublished by Elsevier ,1995
- A model for insulin binding to the insulin receptorEuropean Journal of Biochemistry, 1994
- Deletion of exon 21 of the insulin receptor eliminates tyrosine kinase activity but preserves mitogenic signalingBiochemistry, 1993
- Transmembrane signalling by insulin via an insulin receptor mutated at tyrosines 1158, 1162, and 1163Biochemical and Biophysical Research Communications, 1991